A sponsor had to choose study locations, find eligible patients and run a protocol across clinical sites. Health information was dispersed across providers and data owners, while operational responsibility sat with sponsors and research organizations. A useful plan needed both relevant evidence about patients and the capacity to execute a regulated study. IQ1
IQVIA
IQVIA combined IMS’s health data with Quintiles’ trial operations, giving drugmakers one supplier for choosing where to run studies and carrying them out.
What shaped IQVIA
- 1 · 2016 to 2025Join the information used to plan a trial with the ability to run itIMS Health and Quintiles announced their combination in 2016. IQ1 IQ2
- 2 · 2016 to 2025Maintain reusable health information without confusing size with a learning loopIQVIA’s 2025 filing describes more than 1.2 billion non-identified longitudinal patient records, roughly 150,000 data suppliers and work to standardize and connect disparate information. IQ2 IQ3
- 3 · 2016 to 2025Earn the contract through delivery and carry the obligations that followIQVIA reported $32.7 billion of contracted R&D backlog at the end of 2025 and expected about $8.3 billion to become revenue over the next twelve months. IQ2 IQ4Switching costs
Arena: Market Conditions Before IQVIA
How each step happened
Step 1 of 3 · 2016 to 2025
Join the information used to plan a trial with the ability to run it
IMS Health and Quintiles announced their combination in 2016. The proposed benefit was specific: use health information and analytics to improve protocol design, site selection and recruitment while drawing on Quintiles’ clinical operations. By 2025 the combined company operated data and technology services alongside clinical research. IQ1 IQ2
A sponsor can buy help identifying suitable populations and sites together with the staff and processes that deliver the trial. The combination reduces the organizational distance between analysis and execution. That is a plausible source of differentiation, but the merger announcement’s projected synergies are not evidence that every study became faster or cheaper.
The operating record establishes the combined offer and substantial revenue. It does not isolate the incremental value of ownership over a well-managed supplier partnership.
Rivals ICON and other CROs can run trials, and sponsors can combine a CRO with separate data suppliers. A matched comparison would ask whether integrated information improves recruitment or study delivery for similar protocols.
Step 2 of 3 · 2016 to 2025
Maintain reusable health information without confusing size with a learning loop
IQVIA’s 2025 filing describes more than 1.2 billion non-identified longitudinal patient records, roughly 150,000 data suppliers and work to standardize and connect disparate information. It also warns that suppliers can restrict use, raise prices or stop licensing data. Veeva’s filing documents a dispute over access to IQVIA data in competing applications. IQ2 IQ3
The useful asset includes collection rights, longitudinal linkage and the work of making records comparable. A buyer can reuse this prepared information rather than negotiate and clean each source itself. A rival needs sufficient access and curation to answer the same question. Those are qualified data-access and accumulated-work barriers; more records alone do not prove an exclusive feedback loop or superior clinical predictions.
Patient records are not a count of consenting customers choosing IQVIA. Geographic coverage, permitted uses and dataset quality matter as much as the headline total.
Rivals Veeva and other data suppliers challenge the notion that one company owns every relevant dataset. The licensing dispute establishes a contested boundary around access, not a finding that all restrictions were lawful or that competitors cannot compete.
Step 3 of 3 · 2016 to 2025
Earn the contract through delivery and carry the obligations that follow
IQVIA reported $32.7 billion of contracted R&D backlog at the end of 2025 and expected about $8.3 billion to become revenue over the next twelve months. Contracts can be cancelled or delayed. The company also carried substantial debt. The FTC secured a preliminary injunction against the proposed Propel Media acquisition, preventing the proposed deal from closing. IQ2 IQ4
A live trial is costly to move because the sponsor must preserve site coordination, records and protocol execution. That supports qualified switching costs during a program. It does not ensure that IQVIA wins the sponsor’s next study. As The Investment Log’s analysis stresses, the reusable data business coexists with a labor-intensive, funding-sensitive clinical-services business and a significant financing burden. IQ8
The Propel case concerns healthcare advertising, not a court finding about all clinical-research markets. Trial stickiness and advertising-market concentration are different mechanisms.
Rivals ICON, other CROs and sponsors’ internal teams compete for new programs. Existing backlog is a record of contracted work, not an irrevocable annuity or proof that IQVIA’s data won the contract.
Key dates
- 2016The combination brings healthcare information and clinical operations into one business. IQ1 IQ2 IQ1 IQ2
- 2023-12-29A preliminary injunction prevents completion of the proposed advertising acquisition. IQ4 IQ4
- 2024Veeva discloses litigation over access to IQVIA information in competing applications. IQ3 IQ3
- 2025IQVIA reports $32.7 billion in R&D backlog, subject to timing and cancellation risks. IQ2 IQ2
- 2025IQVIA describes a large supplier network and more than 1.2 billion longitudinal patient records. IQ2 IQ2
Sources
Oldest first.
- IQ1 IMS Health and Quintiles to merge. Primary disclosure
- IQ4 IQVIA Holdings / Propel Media. Regulatory record
- IQ3 Veeva fiscal 2024 annual report. Competitor disclosure
- IQ2 IQVIA 2025 annual report. Primary disclosure
- IQ8 IQVIA: 68 petabytes of healthcare data and $15.8 billion in debt. Outside analysis
- IQ5 IQVIA market capitalization. Market observation